WCTF.org Transplant News

New Facility Meets LEEDS Standards for Sustainable Development

PLEASANTON, Calif., April 3, 2008 /PRNewswire/ -- Roche Molecular Diagnostics (RMD) today announced the opening of its new research facility at the company's global headquarters in Pleasanton, California. The building represents the final phase of consolidation of RMD's West Coast operations into one campus in Pleasanton which now houses close to 500 employees, including 120 members of RMD's research teams previously located in Alameda. RMD is a world-leading molecular diagnostics company, developing diagnostics designed to provide information allowing healthcare providers to select and monitor patient response to therapy or identify molecular characteristics of a disease. RMD's products also help to ensure the safety of blood and blood products before they are used for medical procedures by using its approved systems to screen donations.

RMD is a world-leading molecular diagnostics company, developing diagnostics that provide information to select the best therapy for a particular patient by enabling physicians to monitor response to treatment or identify molecular characteristics of a disease. RMD also supports the safety of the blood supply by using our approved systems to screen donors.

The research building encompasses more than 135,000 square feet on RMD's 33.4 acre campus in the Hacienda Business Park. Designed by a local firm, DES Architects + Engineers under the leadership of Craig Ivancovich, architect and principal, it was then built by another local company, DPR Construction. The building and its surroundings incorporate numerous features designed to ensure successful green building status, construction and operation, and further demonstrate Roche's ongoing commitment to sustained development and environmental efficiency throughout its global operations. Going forward, RMD is working to implement final operational improvements that will enable the new facility to qualify for Leadership in Energy and Environmental Design (LEED) "green building" certification from the US Green Building Council.

"In designing the new building, it was important to us to minimize our environmental footprint while designing a functional space that could support core research functions and state-of-the-art molecular biology research laboratories," said Daniel O'Day, President and CEO. "With the development of this new building, we have achieved these goals while creating an optimal space for our employees to focus on their ongoing contributions to improving healthcare for people around the world."

About RMD

Headquartered in Pleasanton, California, Roche Molecular Diagnostics is the world leader in molecular in vitro diagnostics. A business area of Roche (Basel, Switzerland), RMD develops and manufactures innovative tests based on its Nobel Prize winning polymerase chain reaction (PCR) technology. PCR is the technology that underlies a new generation of medical diagnostics.

RMD supplies a wide array of innovative medical diagnostic products, services, and technologies to researchers, physicians, patients, hospitals and laboratories worldwide. Our marketed diagnostic tests and automated instrument platforms, and those now in development, are focused on blood screening, virology, microbiology, genomics and oncology, and sexually transmitted diseases. For a complete list of our diagnostics and blood screening products, please visit our website at http://molecular.roche.com/

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com/.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Amy Berry
Roche Molecular Diagnostics
Communications
Phone: 925-730-8028
email: amy.berry@contractors.roche.com

First Call Analyst:
FCMN Contact:

Source: Roche Molecular Diagnostics

CONTACT: Amy Berry, Communications, of Roche Molecular Diagnostics,
+1-925-730-8028, amy.berry@contractors.roche.com

Web site:

http://molecular.roche.com/

-------
Profile: Transplant News

London, 3 April/GNN/ --

DEPARTMENT OF HEALTH News Release (2008/0041) issued by The Government News
Network on 3 April 2008
The Department of Health today announced the appointment of a new 'transplant
tsar' to drive forward Government plans to increase the number of people
who can benefit from an organ transplant .

On 16 January, Ministers accepted recommendations made by the Organ Donation
Taskforce and agreed the necessary investment to increase by 50% in five
years the number of donor organs available for transplantation.

To oversee delivery of this programme of work Transplant and Managing
Director at UK Transplant, Mr Chris Rudge has been appointed as National
Clinical Director for Transplant.

Ministers have also asked Prof Sir Bruce Keogh, NHS Medical Director at the
Department of Health, to chair the implementation Group, which has a UK-wide
remit, to support the new Clinical Director

Prof Sir Bruce Keogh, welcomed Mr Rudge to his new role. He said:

"We are delighted that a clinician of Mr Rudge's standing has agreed to work
with us to drive forward implementation of the Organ Donation Taskforce
recommendations and help achieve the significant increases in transplants
that will benefit so many people.

Mr Rudge said:

"I feel privileged to be leading the day-to-day implementation of the Organ
Donation Taskforce recommendations. Organ transplantation is one of medicine's
great success stories but tragically hundreds of people die in the UK every
year because there are not enough organs. I am confident that we can make a
real difference to peoples lives over the next three to five years and will be
working to overcome the barriers to organ donation identified by the Taskforce
and deliver the increase in transplants that is so desperately needed.'

Chris Rudge was appointed UK Transplant's first Medical Director in 2001 to
provide clinical leadership and has played a wide role in developing working
relationships between UKT, the clinical transplant programmes in the UK and
the critical care community. He was consultant transplant surgeon at Guy's
Hospital and then St Peter's Hospital.

In 1995 he became Director of Transplantation at The Royal London Hospital,
where he continues to spend one day a week. Mr Rudge will be joining the
Department of Health but at the same time he will continue to be responsible
for the day to day running of UK Transplant until a permanent replacement
is appointed. His responsibilities also include liaising with those in the
other UK Health Departments responsible for implementing the recommendations
in their country.

Notes to editors

1. Mr Rudge will undertake his role as National Clinical Director for
Transplant on secondment to the Department of Health for three years.
His work as National Clinical Director will begin shortly once transitional
arrangements at UK Transplant are in place. As part of these arrangements,
Lynda Hamlyn, the Chief Executive of NHS Blood and Transplant (NHSBT) will
take responsibility for the implementation of the Taskforce recommendations
that fall to NHSBT.

2. The Organ Donation Taskforce was established by the Government in 2006
to identify barriers to organ donation. The Taskforce was comprised of 20
members including patients, transplant surgeons, critical care specialists,
donor transplant co-ordinators, NHS managers, the other Health Departments in
the UK and representatives from the media, clinical ethics, diversity issues
and charities. In developing its recommendations the Taskforce consulted a
number of experts, including those from Spain, USA and Australia.

3. The Taskforce was asked to identify barriers to organ donation,
explore current issues that might have a bearing on donation rates, and
recommend action to be taken to increase organ donation within current legal
frameworks. Their Report published on 16 January contained 14 recommendations
covering the need to invest in better donor identification and referral,
better donor coordination and improved organ retrieval arrangements. The
UK Government has committed £11m extra funding in 2008/08 to support
implementation, and each of the other countries is committed to implementation.

4. The full Report of the taskforce- Organs for Transplants. A Report from
the Organ Donation Taskforce, is available at www.dh.gov.uk

5. In September 2007, following the publication of the Chief Medical Officer's
annual report which recommended a move to presumed consent for organ donation,
the Secretary of State for Health Alan Johnson asked the Taskforce to look
at the issue of presumed consent as a second piece of work.. The issue of
presumed consent was not included in the Report published on 16 January .
A separate report will follow in the summer.

6. Currently, more than 8,000 people in the UK need an organ transplant,
rising by about 8% a year. At the end of March 2007, 7,219 patients were
listed as actively waiting for a transplant. More information is available
on www.uktransplant.org.uk

7. UK Transplant is the NHS organisation responsible for matching and
allocating donated organs. It is part of NHS Blood and Transplant (NHSBT), a
Special Health Authority within the NHS that manages the National Blood Service
and transplants. This part of its responsibilities covers the whole of the UK.

For media enquiries only, please contact the Department of Health News desk
on 0207 210 5221

For public enquiries, please call 020 7210 4850

[ENDS]

Source: Department of Health

-------
Profile: Transplant News